Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Blood (2024) 144 (Supplement 1): 6188.

https://doi.org/10.1182/blood-2024-207123

Published: 2024

Journal Articles

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Blood (2022) 140 (Supplement 1): 7560–7562.

https://doi.org/10.1182/blood-2022-163360

Published: 2022

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma

Blood (2015) 125 (1): 124–132.

https://doi.org/10.1182/blood-2014-08-594507

Published: 2015

Includes: Supplemental data

Journal Articles

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL

Blood (2013) 122 (13): 2242–2250.

https://doi.org/10.1182/blood-2013-06-508028

Published: 2013

Includes: Supplemental data

Journal Articles

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

Unn-Merete Fagerli, MD, PhD, Thorsten Stühmer, PhD, Toril Holien, Randi Utne Holt, PhD, Ove Bruland, PhD, Manik Chatterjee, MD, John Shaughnessy, Jr, PhD, Stephan Mathas, MD, Anders Sundan, MD, Ralf C Bargou, MD, Bernd Dörken, MD, Magne Borset, MD, PhD, Martin Janz, MD

Blood (2010) 116 (21): 1915.

https://doi.org/10.1182/blood.V116.21.1915.1915

Published: 2010

Journal Articles

High-Level Expression of Mastermind-Like 2 (MAML2) Contributes to Aberrant Activation of the NOTCH Signaling Pathway In Human Lymphomas

Karl Köchert, Stephan Kreher, Jon C Aster, MD, PhD, Motoo Kitagawa, Korinna Jöhrens, Ioannis Anagnostopoulos, Franziska Jundt, MD, PD, Harald Stein, MD, Martin Janz, MD, Bernd Dörken, MD, Stephan Mathas, MD

Blood (2010) 116 (21): 2685.

https://doi.org/10.1182/blood.V116.21.2685.2685

Published: 2010

Journal Articles

C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells

Rekha Pal, Martin Janz, Deborah L. Galson, Margarete Gries, Shirong Li, Korinna Jöhrens, Ioannis Anagnostopoulos, Bernd Dörken, Markus Y. Mapara, Lisa Borghesi, Lela Kardava, G. David Roodman, Christine Milcarek, Suzanne Lentzsch

Blood (2009) 114 (18): 3890–3898.

https://doi.org/10.1182/blood-2009-01-201111

Published: 2009

Includes: Supplemental data

Journal Articles

Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts T reg cells via regulation of MIP-3α

Björn Lamprecht, Stephan Kreher, Ioannis Anagnostopoulos, Korinna Jöhrens, Giovanni Monteleone, Franziska Jundt, Harald Stein, Martin Janz, Bernd Dörken, Stephan Mathas

Blood (2008) 112 (8): 3339–3347.

https://doi.org/10.1182/blood-2008-01-134783

Published: 2008

Includes: Supplemental data

Journal Articles

C/EBPβ Is a Critical Factor for Proliferation and Apoptosis in MM Cells by Controlling Transcription Factors Like IRF-4, PAX5 and Blimp1.

Rekha Pal, PhD, Martin Janz, PhD, Deborah Galson, PhD, Suzanne Lentzsch, MD, PhD

Blood (2007) 110 (11): 1506.

https://doi.org/10.1182/blood.V110.11.1506.1506

Published: 2007

Journal Articles

Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells

Martin Janz, Michael Hummel, Matthias Truss, Brigitte Wollert-Wulf, Stephan Mathas, Korinna Jöhrens, Christian Hagemeier, Kurt Bommert, Harald Stein, Bernd Dörken, Ralf C. Bargou

Blood (2006) 107 (6): 2536–2539.

https://doi.org/10.1182/blood-2005-07-2694

Published: 2006

Includes: Supplemental data

Journal Articles

Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas

Stephan Mathas, Korinna Jöhrens, Stefan Joos, Andreas Lietz, Franziska Hummel, Martin Janz, Franziska Jundt, Ioannis Anagnostopoulos, Kurt Bommert, Peter Lichter, Harald Stein, Claus Scheidereit, Bernd Dörken

Blood (2005) 106 (13): 4287–4293.

https://doi.org/10.1182/blood-2004-09-3620

Published: 2005

Journal Articles

Non-Genotoxic Targeting of p53-Dependent and p53-Independent Signaling Pathways Efficiently Kills Hodgkin/Reed-Sternberg Cells.

Martin Janz, MD, Thorsten Stühmer, PhD, Bernd Dörken, MD, Ralf Bargou, MD

Blood (2005) 106 (11): 964.

https://doi.org/10.1182/blood.V106.11.964.964

Published: 2005

Journal Articles

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis

Ki-Ryang Koh, Martin Janz, Markus Y. Mapara, Britt Lemke, David Stirling, Bernd Dörken, Martin Zenke, Suzanne Lentzsch

Blood (2005) 105 (10): 3833–3840.

https://doi.org/10.1182/blood-2004-03-0828

Published: 2005

Journal Articles

Immunomodulatory Effects of CC-4047 on Hematopoietic Progenitors Are Associated with a Shift in the Cytokine Secretion Profile Favoring Myeloid Differentiation.

Margarethe Gries, Markus Y. Mapara, David Stirling, Martin Janz, Suzanne Lentzsch

Blood (2004) 104 (11): 2917.

https://doi.org/10.1182/blood.V104.11.2917.2917

Published: 2004

Journal Articles

Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis

Stephan Mathas, Andreas Lietz, Martin Janz, Michael Hinz, Franziska Jundt, Claus Scheidereit, Kurt Bommert, Bernd Dörken

Blood (2003) 102 (3): 1028–1034.

https://doi.org/10.1182/blood-2002-04-1154

Published: 2003

Journal Articles

Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

Suzanne Lentzsch, Margarete Gries, Martin Janz, Ralf Bargou, Bernd Dörken, Markus Y. Mapara

Blood (2003) 101 (9): 3568–3573.

https://doi.org/10.1182/blood-2002-08-2383

Published: 2003

NARROW

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

High-Level Expression of Mastermind-Like 2 (MAML2) Contributes to Aberrant Activation of the NOTCH Signaling Pathway In Human Lymphomas

C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells

Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts T reg cells via regulation of MIP-3α

C/EBPβ Is a Critical Factor for Proliferation and Apoptosis in MM Cells by Controlling Transcription Factors Like IRF-4, PAX5 and Blimp1.

Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells

Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas

Non-Genotoxic Targeting of p53-Dependent and p53-Independent Signaling Pathways Efficiently Kills Hodgkin/Reed-Sternberg Cells.

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis

Immunomodulatory Effects of CC-4047 on Hematopoietic Progenitors Are Associated with a Shift in the Cytokine Secretion Profile Favoring Myeloid Differentiation.

Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis

Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only